Immunotherapy combined with definitive chemoradiotherapy for locally advanced unresectable esophageal squamous cell carcinoma
ICIs combined with concurrent dCRT demonstrated promising efficacy and manageable safety in patients with unresectable LA-ESCC.
Authors
- Yong Sang Hong (ORCID: https://orcid.org/0000-0001-5672-0072)
- Yinan Wu
- Ning Jiang (ORCID: https://orcid.org/0000-0002-9851-0863)
- Lijun Zhao
- Yu Chen (ORCID: https://orcid.org/0000-0001-9420-1636)
- Yixin Li (ORCID: https://orcid.org/0000-0001-8740-5040)
- Xiangzhi Zhu
- Yang Zhao (ORCID: https://orcid.org/0009-0008-4044-3785)
- Bo Yang (ORCID: https://orcid.org/0000-0002-1748-9514)
- Qiang‐Wu Tan (ORCID: https://orcid.org/0009-0009-4953-199X)
- Lingling Gu
- Zihao Zhu
Institutions
- Jiangsu Cancer Hospital (CN)
- Second Affiliated Hospital of Nanjing Medical University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-09-30
- DOI
- https://doi.org/10.3389/fimmu.2025.1646568
- Citations
- 1
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.01
Funders
- Government of Jiangsu Province
- Wu Jieping Medical Foundation
- Jiangsu Cancer Hospital